Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NHS

Cancer drugs fund did not provide meaningful value to patients, say researchers

patient receiving chemotherapy drugs

Source: Shutterstock.com

Some anti-cancer drugs provided under the Cancer Drugs Fund might have exposed some patients to unnecessary side effects, researchers have concluded

The NHS Cancer Drugs Fund (CDF) has not provided meaningful value to cancer patients and wider society and may have unnecessarily exposed patients to adverse drug reactions, according to a study published in the Annals of Oncology.

The researchers focused on 29 cancer drugs approved for 47 indications that could be prescribed through the CDF in January 2015. They analysed the potential value delivered by the CDF according to six value criteria: evidence of drug efficacy; effectiveness in ‘real world’ populations; value according to the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO); cost effectiveness according to the National Institute for Health and Care Excellence (NICE) thresholds; CDF’s own audit; and value delivered to NHS patients.

Of the 47 indications: only 38% reported a statistically significant overall survival benefit; 48% and 18% met ASCO and ESMO criteria, respectively; 55% of the indications had been rejected by NICE because they did not meet its cost-effectiveness thresholds; and 13 were delisted in 2015 due to insufficient evidence for clinical benefit.

The researchers concluded that there was no evidence to support a “drug only” ring-fenced cancer fund and that decisions for all drugs and interventions should be made through appropriate health technology appraisal processes.

“We recommend that other countries that are considering similar ring-fenced drug access funds for high-cost cancer drugs should adopt a more rational approach to funding high-cost health technologies” says Richard Sullivan, director of the Institute of Cancer Policy at King’s College London and co-author of the study.

The CDF was originally established in 2010 to improve access to cancer drugs not available through the NHS due to not being appraised, being in the process of being appraised or already appraised but not recommended by NICE.

After £1.27bn expenditure and following a three-month parliamentary review, the CDF was rationalised back into NICE in 2016.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202676

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • patient receiving chemotherapy drugs

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.